drugset
Drugs / Quadrivalent Influenza Vaccine (QIV)
last change Feb 2025 re-read 3 minutes ago

Quadrivalent Influenza Vaccine (QIV)

also known as CSL QIV · IIV4

Vaccine

Developed for
influenza
Investigated by
Seqirus

Trials 1

today NCT02214225 · Ph 3
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial · 1 met primary
Phase 3 NCT02214225 Aug → Nov 2014 influenza Seqirus Completed Met primary
Comparator or background therapy1 trial
Phase 1/2 NCT06436703 Comparator May 2024 → Feb 2025 influenza Pfizer Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Quadrivalent Influenza Vaccine (QIV) ClinicalTrials.gov intervention name — accepted as the source's own label NCT06436703 ↗
1

NCT02214225 ↗
Known as CSL QIV “a Quadrivalent Influenza Vaccine (CSL QIV) in Comparison With a US Licensed 2014/2015 Trivalent Influenza Vaccine” NCT02214225 ↗
Known as IIV4 “a quadrivalent inactivated influenza vaccine (IIV4) versus the United States (US)-licensed 2014-2015 trivalent inactivated influenza vaccine” PMID 28302411 ↗ Mar 2017
Modality Vaccine “a quadrivalent inactivated influenza vaccine (IIV4)” PMID 28302411 ↗ Mar 2017
Route Intramuscular “One 0.5 mL intramuscular dose into the deltoid muscle” NCT02214225 ↗